Actively Recruiting
Comparing Telitacicept and Conventional Immunosuppressive Therapy in Primary Sjgrens Disease with Interstitial Lung Disease A Prospective Cohort Study
Led by Peking University People's Hospital · Updated on 2026-09-28
60
Participants Needed
1
Research Sites
9 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the real-world effectiveness of Telitacicept compared with conventional immunosuppressive therapy in patients with primary Sjgrens disease associated with interstitial lung disease. This open-label, single-center cohort study involves 60 participants confirmed to have interstitial lung disease by high-resolution computed tomography. The study aims to assess lung function changes over 24 weeks, focusing on forced vital capacity percent predicted. Participants are divided into two groups based on the treatment chosen by their doctors and preferences. One group receives Telitacicept 160 mg by subcutaneous injection once weekly for 24 weeks alongside their usual background therapy, such as hydroxychloroquine or other immunosuppressive agents. The other group receives only the background therapy without Telitacicept, with both groups followed regularly using the same schedule. Throughout the 24 weeks, participants undergo assessments including lung function tests like forced vital capacity and diffusing capacity for carbon monoxide, total lung capacity, and high-resolution CT scans scored by the Warrick method. Blood tests measuring biomarkers such as KL-6 and disease activity indices like ESSDAI are also performed. Researchers explore changes in B-cell subsets and related biomarkers to understand their association with lung outcomes. This monitoring helps evaluate treatment effects and safety during the study period.
CONDITIONS
Brief Title
Clinical Efficacy of Telitacicept in Sjögren's Disease With Interstitial Lung Disease
Research Team
J
Jing Ning
Y
Yuan Jia
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here